Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Other Non-Current Assets: 2020-2021

  • SAB Biotherapeutics' Other Non-Current Assets rose 5471.24% to $13.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was $13.1 million, marking a year-over-year increase of 5471.24%. This contributed to the annual value of $13.1 million for FY2021, which is 5471.24% up from last year.
  • Per SAB Biotherapeutics' latest filing, its Other Non-Current Assets stood at $13.1 million for Q4 2021, which was up 5,471.24% from $235,111 recorded in Q4 2020.
  • In the past 5 years, SAB Biotherapeutics' Other Non-Current Assets ranged from a high of $13.1 million in Q4 2021 and a low of $235,111 during Q4 2020.
  • Moreover, its 2-year median value for Other Non-Current Assets was $6.7 million (2020), whereas its average is $6.7 million.
  • Data for SAB Biotherapeutics' Other Non-Current Assets shows a peak YoY skyrocketed of 5,471.24% (in 2021) over the last 5 years.
  • Quarterly analysis of 2 years shows SAB Biotherapeutics' Other Non-Current Assets stood at $235,111 in 2020, then surged by 5,471.24% to $13.1 million in 2021.